142 related articles for article (PubMed ID: 14735554)
21. Effective palliation by low dose local radiotherapy for recurrent and/or chemotherapy refractory non-follicular lymphoma patients.
Haas RL; Poortmans P; de Jong D; Verheij M; van der Hulst M; de Boer JP; Bartelink H
Eur J Cancer; 2005 Aug; 41(12):1724-30. PubMed ID: 16039113
[TBL] [Abstract][Full Text] [Related]
22. Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey.
Lauria F; Rondelli D; Zinzani PL; Bocchia M; Marotta G; Salvucci M; Raspadori D; Ventura MA; Birtolo S; Forconi F; Tura S
Leukemia; 1997 May; 11(5):629-32. PubMed ID: 9180283
[TBL] [Abstract][Full Text] [Related]
23. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Al-Batran SE; Kim SZ; Welslau M; Hecker R; Kofahl-Krause D; Josten KM; Dürk H; Rost A; Neise M; von Grünhagen U; Chow KU; Hansmann ML; Hoelzer D; Mitrou PS
J Clin Oncol; 2005 May; 23(15):3383-9. PubMed ID: 15908650
[TBL] [Abstract][Full Text] [Related]
24. Nodal and splenic marginal zone B cell lymphomas.
Mollejo M; Camacho FI; Algara P; Ruiz-Ballesteros E; García JF; Piris MA
Hematol Oncol; 2005; 23(3-4):108-18. PubMed ID: 16307458
[TBL] [Abstract][Full Text] [Related]
25. State-of-the-art therapeutics: marginal-zone lymphoma.
Bertoni F; Zucca E
J Clin Oncol; 2005 Sep; 23(26):6415-20. PubMed ID: 16155028
[TBL] [Abstract][Full Text] [Related]
26. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial.
Ferreri AJ; Ponzoni M; Guidoboni M; Resti AG; Politi LS; Cortelazzo S; Demeter J; Zallio F; Palmas A; Muti G; Dognini GP; Pasini E; Lettini AA; Sacchetti F; De Conciliis C; Doglioni C; Dolcetti R
J Natl Cancer Inst; 2006 Oct; 98(19):1375-82. PubMed ID: 17018784
[TBL] [Abstract][Full Text] [Related]
27. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.
Buckstein R; Kerbel RS; Shaked Y; Nayar R; Foden C; Turner R; Lee CR; Taylor D; Zhang L; Man S; Baruchel S; Stempak D; Bertolini F; Crump M
Clin Cancer Res; 2006 Sep; 12(17):5190-8. PubMed ID: 16951238
[TBL] [Abstract][Full Text] [Related]
28. Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma.
Oh SY; Ryoo BY; Kim WS; Kim K; Lee J; Kim HJ; Kwon JM; Lee HR; Ko YH; Oh SJ; Park KW; Kim HJ; Kwon HC; Nam E; Kim JH; Park YH; Lee SS; Kim HY; Park K
Ann Hematol; 2006 Nov; 85(11):781-6. PubMed ID: 16847665
[TBL] [Abstract][Full Text] [Related]
29. Treatment options for primary splenic low-grade non-Hodgkin's lymphomas.
Musteata VG; Corcimaru IT; Iacovleva IA; Musteata LZ; Suharschii IS; Antoci LT
Clin Lab Haematol; 2004 Dec; 26(6):397-401. PubMed ID: 15595997
[TBL] [Abstract][Full Text] [Related]
30. [Splenic marginal zone lymphoma associated with autoimmune hemolytic anemia treated with splenectomy and rituximab].
Miztani M; Noda T; Umino A; Tanigawa M; Taniguchi M; Tamaki S; Tsuji K
Rinsho Ketsueki; 2007 Nov; 48(11):1489-91. PubMed ID: 18080507
[TBL] [Abstract][Full Text] [Related]
31. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma.
Olszewski AJ
Am J Hematol; 2012 Nov; 87(11):E119-22. PubMed ID: 22887176
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
33. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
34. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases.
Oh SY; Kim WS; Kim SJ; Kim JS; Kim SH; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Kim JG; Yang DH; Kang HJ; Choi CW; Park J; Choi YJ; Kim HJ; Kwon JH; Suh C; Kim HJ
Am J Hematol; 2009 Dec; 84(12):826-9. PubMed ID: 19890833
[TBL] [Abstract][Full Text] [Related]
35. Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?
Kalpadakis C; Pangalis GA; Vassilakopoulos TP; Sachanas S; Angelopoulou MK
Leuk Lymphoma; 2014 Jul; 55(7):1463-70. PubMed ID: 24050506
[TBL] [Abstract][Full Text] [Related]
36. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines.
Rigacci L; Mappa S; Nassi L; Alterini R; Carrai V; Bernardi F; Bosi A
Hematol Oncol; 2007 Dec; 25(4):198-203. PubMed ID: 17654614
[TBL] [Abstract][Full Text] [Related]
37. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
38. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
39. Rituximab monotherapy for splenic marginal zone lymphoma.
Bennett M; Sharma K; Yegena S; Gavish I; Dave HP; Schechter GP
Haematologica; 2005 Jun; 90(6):856-8. PubMed ID: 15951303
[TBL] [Abstract][Full Text] [Related]
40. Excellent prognosis and prevalence of HCV infection of primary hepatic and splenic non-Hodgkin's lymphoma.
De Renzo A; Perna F; Persico M; Notaro R; Mainolfi C; de Sio I; Ciancia G; Picardi M; Del Vecchio L; Pane F; Rotoli B
Eur J Haematol; 2008 Jul; 81(1):51-7. PubMed ID: 18397390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
